- Nucleic acid aptamers
- Peptide aptamers
Aptamers Market size was USD 252.3 million in 2022 and is poised to grow at a CAGR of 16.89% from 2023-2029. owing to rise in the investment in biotechnology and pharmaceutical companies for R&D activities, technological developments, an increase in the therapeutic application anticipated to fuel the aptamers market over the forecast period. Furthermore, increase in the using of aptamers in metabolism drug discovery, entry of private organizations in research and development space, and advantages of aptamers over other therapeutics expected to drive the market. However, stringent regulatory policies and ethical issues in aptamers usage, dearth of aptamers in the market in the undeveloped regions, and lack of awareness about the aptamers usage expected to dampen the growth of aptamers market over the forecast period. Aptamers are the single-stranded peptide or oligonucleotide molecules that bind to the protein, nucleic acid molecules or target lipid with the high specificity. Aptamers are used in pharmaceutical studies, laboratory diagnosis, drug discovery, molecular recognition, and treatment of certain diseases. In addition, aptamers are also used in the production of cost-effective and improved medicines, the advantages of aptamers over protein therapeutics include in terms of synthetic accessibility, modification, and size. Aptamers are commonly used in the treatment of AIDS owing to faster development than the antibodies which lead to curing of diseases very faster. Aptamers are single-stranded DNA and RNA molecules that can bind to a specific target with high specificity. Aptamers come in a range of forms thanks to their proclivity for forming helices and single-stranded loops. These can be made fast and used to inhibit and characterise proteins, and they can also be designed to have improved specificity and affinity. These flexible compounds bind to a variety of targets, including proteins, peptides, small molecules, toxins, carbohydrates, and even live cells. Aptamers are usually produced through a selection process from a vast pool of random sequences, and they can be used in both therapeutic and scientific settings.
Fastest Growing Market
Nowadays, Aptamers market is the growing stage with an increase in R&D activities by the various biopharmaceutical companies and research institutes. Technological advancements and drug innovations are expected to fuel the market. For instance, in 2014, MIT scientists created DNA-based drug targeting system comprising of aptamers and ultraviolet light which leads to binding of aptamers with high specificity. Acquisitions and mergers, collaborations, newer technologies launches, fundraising for aptamers development and patent approvals are some key strategies adopted by the companies to increase their share in the global market. For instance, in February 2012, Valent pharmaceutical acquired Eyetech and enters into the aptamers market with the marketing of Macugen anti-VEGF aptamers in U.S. Moreover, in February 2016, researchers from Institute of Bioengineering and Nanotechnology (Singapore) have developed more efficient DNA technology for detection and treatment of cancer and infectious diseases.
The aptamers market size was valued at USD 252.3 million in 2022
High Advantage of Aptamers, Compared to Antibodies
Europe is the fastest-growing for aptamers market